# Pizarra — PT-pseudo_175e6ad47991 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_175e6ad47991
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 79-year-old male
  - PSA: 28.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.28 ng/mL²
  - PSA velocity: 2.75 ng/mL/yr
  - Prior PSA: 16.6 ng/mL
  - Prostate volume: 100.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.3807473 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 28 ng/mL. PI-RADS 5. PSAD 0.28. Prostate volume 100 mL. csPCa 0.38.

Vitals: weight 88 kg, height 183 cm, BMI 26.3, BP 130/64 mmHg, HR 84 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2002).

Chief complaint: Evaluation of a marked serum prostate-specific antigen increase to 28.0 ng/mL alongside reassessment of previously negative biopsy results.

History: Residing in a ground-floor apartment with his wife, the seventy-nine-year-old retired warehouse worker first came to attention regarding a prostate-specific antigen elevation documented in mid-2022. He maintains a steady lifestyle featuring weekly swimming sessions and moderate alcohol intake averaging 20 units weekly. Mild lower urinary tract symptoms are present, corresponding to an IPSS score of 9, though acute urinary retention and haematuria are absent. Past medical history remains clear save for an appendectomy performed in his youth and a recent routine cognitive screening at a memory clinic. Ex-smoker (30 pack-yr, quit 2002). Participation in any prostate cancer research trials was previously declined. Comorbidities are absent, and he takes no active medications.

Physical examination: DRE: Normal. Prostate is symmetrically enlarged with smooth, firm consistency and no palpable asymmetry or discrete nodules. General examination remains within normal limits, featuring stable vitals and absent lymphadenopathy or bone tenderness. Abdominal palpation is soft and non-tender, with a palpable bladder correlating with the documented prostate volume.

Patient info: retired warehouse worker; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 20 units / week; exercise Swimming 1x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Audiology — hearing test; Memory clinic — baseline screening.
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.59 +/- 0.21   (95% CI 0.16-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 3.6 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=28.0, age=79.0, psad=0.28, dre_ord=0.0, vol=100.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=28.0, Age=79, PSA Density=0.28, DRE=Normal, Volume=100.0 mL, Prior Biopsy=Negative, csPCa probability=0.3807473). It cannot weigh the significance of the PSA velocity (2.75 ng/mL/yr) or the specific context of the PI-RADS 5 score in relation to the prior negative biopsy.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a wide uncertainty interval (0.59 +/- 0.21), indicating the classifier is highly uncertain. This uncertainty means the suggestion could be wrong because the statistical model cannot distinguish between the clinical scenarios that lead to a positive or negative outcome. Specifically, the prior might be wrong because a prior negative biopsy, combined with a high PI-RADS 5 score, might strongly favor active surveillance (AS) if other factors (like PSA density or PSA velocity) are favorable, which the prior failed to weigh adequately.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_175e6ad47991", "radiology_report": "Subject: Prostate Multiparametric MRI | Facility: OLVG Amsterdam | Date: 15 Dec 2024\n\nClinical Indication: Evaluation of rising PSA (28.0 ng/mL) and re-evaluation following prior negative biopsy.\n\nFINDINGS:\nThe gland demonstrates marked hypertrophy, occupying approximately 100.0 mL. T2-weighted sequences highlight a discrete hypointense focus within the right posterior peripheral zone, spanning the base through the mid-gland. Maximum dimension reaches 25 mm. Diffusion-weighted imaging shows pronounced restriction with matching ADC hypointensity. Dynamic contrast sequences capture early, focal enhancement. There is no evidence of capsular breach, seminal vesicle invasion, nodal enlargement, or osseous metastasis.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right posterior peripheral zone (base-to-mid), approximately 25 mm.\nProstate volume: 100.0 mL.\nPSA density: 0.28 ng/mL/mL.\ncsPCa predicted probability 0.3807473."}
get_psa_trend
{"case_id": "PT-pseudo_175e6ad47991", "psa_trend": [{"date": "Jun 2022", "val": 2.5}, {"date": "Feb 2023", "val": 4.7}, {"date": "Sep 2023", "val": 8.9}, {"date": "May 2024", "val": 16.8}, {"date": "Jan 2025", "val": 28.0}]}
get_previous_notes
{"case_id": "PT-pseudo_175e6ad47991", "previous_notes": [{"date": "08 May 2024", "author": "Dr. L. Smits (GP)", "text": "Clinical records indicate a review for sustained prostate-specific antigen elevation. Earlier testing in September 2023 registered 18.3 ng/mL, while the most recent assay on 08 May 2024 showed 16.6 ng/mL. Following review of this trend and the prior biopsy bucket \"Negative\", a repeat serum test was ordered alongside standard chemistry panels. Results were communicated, and coordination for a urology outpatient visit was initiated."}]}
get_lab_results
{"case_id": "PT-pseudo_175e6ad47991", "laboratory_results": [{"name": "PSA", "val": "28.0 ng/mL", "date": "30 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.34 ng/mL", "date": "30 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "30 Nov 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "11.7 g/dL", "date": "30 Nov 2024", "flag": "L"}, {"name": "WBC", "val": "8.5 x10^9/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "248 x10^9/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "82 umol/L", "date": "30 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "30 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "9.7 nmol/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "85 U/L", "date": "30 Nov 2024", "flag": ""}, {"name": "LDH", "val": "181 U/L", "date": "30 Nov 2024", "flag": "L"}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- mpMRI report: PI-RADS 5 lesion in the right posterior peripheral zone, approximately 25 mm.
- PSA trend: Rising trajectory from 2.5 ng/mL (Jun 2022) to 28.0 ng/mL (Jan 2025), with a velocity of 2.75 ng/mL/yr.
- Previous notes: Patient was on a surveillance protocol following a prior negative biopsy.

AGAINST Sampling:
- DRE findings: Normal.
- Lab results: %Free PSA is 12% (borderline, but not explicitly flagged as a confounder).

WHERE THIS LEANS
The high PI-RADS 5 score and the significant PSA velocity strongly support proceeding with a targeted biopsy to characterize the lesion, aligning with the EXPERT-PROTOCOL criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The guideline criterion strongly supports a repeat biopsy due to the PI-RADS 5 lesion, which is decisive. This is further supported by the significant PSA velocity of 2.75 ng/mL/yr and the rising PSA trend from 16.6 ng/mL to 28.0 ng/mL. The retrieved mpMRI report explicitly identifies a PI-RADS 5 lesion, which is the key finding that overturns the prior negative biopsy status and mandates further sampling.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
